300 Boston Scientific Way
Marlborough, Massachusetts 01752-1291
No summary available.
Bengaluru (Karnataka) [India], August 16 (ANI/PRNewswire): GE Healthcare, a leading global medical technology, diagnostics and digital solutions innovator, today announced its collaboration with Boston Scientific, a global medical device manufacturer, to provide end-to-end innovative interventional cardiac care solutions in India. The collaboration will enable easier access to treatment and is intended to improve heart care […]
The first of its kind collaboration between the two global medtech companies in India, will offer advanced medical devices and capabilities from Boston Scientific, coupled with GE Healthcare’s strong medical imaging systems like cardiac catherization lab and related software, support diagnostics through treatment and monitoring of the cardiac patient-care pathway.
On Tuesday, Wipro GE Healthcare and Boston Scientific announced a collaboration to provide end-to-end innovative interventional cardiac care solutions in India. This collaboration is likely to enable easier access to cardiac treatment. It aims to improve heart care for patients, thereby addressing the menace of the disease prevailing in the… The post Wipro GE Healthcare and Boston Scientific Collaborate to Provide Cardiac Care in India appeared first on Equitypandit .
Boston Scientific Corporation (NYSE: BSX) acquired Obsidio, Inc., a company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature. The amount of the deal was not disclosed. The transaction is expected to be immaterial to Boston Scientific’s GAAP and adjusted earnings per share in 2022. Embolization […] The post Boston Scientific Acquires Obsidio appeared first on FinSMEs .
Boston Scientific (BSX) acquired privately-held Obsidio, a developer of Gel Embolic Material ((GEM)) technology used for embolization of blood vessels in the peripheral…
WASHINGTON (dpa-AFX) - Medical technology company Boston Scientific Corp. (BSX) announced Monday the acquisition of privately-held company Obsidio, Inc. that has developed the Gel Embolic Material…
QY Research has recently published a new report, titled Global Permanent Pacemaker Market Research Report 2022. The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Permanent Pacemaker market.
Boston Scientific Corporation (NYSE:BSX) traded at $41.82 at close of the session on Wednesday, August 10, made an upward move of 1.93% on its previous day’s price. Looking at the stock we see that its previous close was $41.03 and the beta (5Y monthly) reads 0.83 with the day’s price range being $40.795 – $41.155. … What Do Wall Street Analysts Think About Boston Scientific Corporation (NYSE: BSX) Stock? Read More »
New Jersey, NJ -- ( SBWIRE ) -- 08/10/2022 -- Latest Study on Industrial Growth of Connected Healthcare Market 2022-2028. A detailed study accumulated to offer Latest insights about acute features of the Connected Healthcare market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis. The Major Players Covered in this Report: Accenture, IBM, SAP, GE Healthcare, Oracle, Microsoft, Airstrip Technology, Medtronic, Allscripts, Boston Scientific, Athenahealth, Cerner, Philips, Agamatrix, Qualcomm & AliveCor Connected Healthcare Market Study guarantees you to remain / stay advised higher than your competition.
Coherent Market Insights provides an encyclopedic study of the Endovascular Aneurysm Repair (EVAR) Market with holistic insights into important factors and aspects impacting the future growth of the market. The Endovascular Aneurysm Repair (EVAR) Market has been analyzed for the
The Health Care Sector ETF has beaten the S&P 500 this year, but there has been recent relative weakness. BSX recently impressed the Street, click to read why.
Medical-device maker Boston Scientific Corp has agreed to pay Nevro Corp $85 million to settle their patent dispute over spinal-stimulation technology, despite winning $20 million from Nevro at trial last year, the companies said.
In trading on Tuesday, shares of Boston Scientific Corp. (Symbol: BSX) crossed above their 200 day moving average of $41.59, changing hands as high as $41.61 per share. Boston Scientific Corp. shares are currently trading up about 1.2% on the day. The chart below shows the on
Boston Scientific (BSX) and Nevro (NVRO) said they reached a settlement in their intellectual property litigations.Under the agreement, Boston Scientific will pay net $85M and…
WASHINGTON (dpa-AFX) - Medical device makers Nevro Corp. (NVRO) and Boston Scientific Corp. (BSX) announced Monday that they have reached a settlement in all their ongoing intellectual property li…
Boston Scientific Corp (NYSE: BSX) Q2 2022 earnings call dated Jul. 27, 2022 Corporate Participants: Lauren Tengler — Director of Investor Relations Michael F. Mahoney — Chairman, President and Chief Executive Officer Daniel J. […] The post Boston Scientific Corp (BSX) Q2 2022 Earnings Call Transcript first appeared on AlphaStreet .
Boston Scientific Corp (NYSE: BSX) Q2 2022 earnings call dated Jul. 27, 2022
BSX earnings call for the period ending June 30, 2022.
Boston Scientific Corporation (NYSE:NYSE:BSX) Q2 2022 Results Conference Call July 27, 2022 08:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney…
Boston Scientific narrowly topped second-quarter estimates Tuesday, but BSX stock surged higher in premarket action.
Boston Scientific (BSX) stock rose +3% premarket July 27 after the company''s Q2 results beat analysts estimates despite narrowing FY22 outlook. Q2 adjusted EPS rose +10% Y/Y to…
Boston Scientific Earnings, Revenue Beat in Q2
Boston Scientific (NYSE: BSX ) reported its Q2 earnings results on Wednesday, July 27, 2022 at 06:30 AM. Here''s what investors need to know about the announcement. Earnings Boston Scientific beat estimated earnings by 4.76%, reporting an EPS of $0.44 versus … Full story available on Benzinga.com
Boston Scientific Tops Q2 EPS by 2c
Boston Scientific Corp. undefined reported Wednesday second-quarter profit and sales that topped expectations, but trimmed its full-year outlook, saying it…
Boston Scientific (BSX) is scheduled to announce Q2 earnings results on Wednesday, July 27th, before market open.The consensus EPS Estimate is $0.42 (+5.0% Y/Y) and the consensus…
New York, 2022-Jul-14 — /EPR Network/ — Global Vascular Plugs Market report from Global Insight Services is the single authoritative source of intelligence on Vascular [read full press release…]
Baker Hughes Company (BKR) with the stream of 3.90% also noticed, India Boston Scientific Corporation (BSX) encountered a rapid change of 1.45% in the last hour of Tuesday’s trading session. … The post Sizzling Stock: Baker Hughes Company (NASDAQ:BKR), Boston Scientific Corporation (NYSE:BSX) appeared first on Stocks Equity .
Johnson & Johnson (NYSE: JNJ ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. Boston Scientific The Trade: Boston Scientific Corporation (NYSE: BSX ) EVP, Human Resources Wendy Carruthers sold a total of 7,500 shares at an average price of $38.00. The … Full story available on Benzinga.com
Boston Scientific Corporation with ticker code (BSX) now have 26 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 55.5 and 43 and has a mean target at 48.8. With the stocks previous close at 36.71 this indicates there is a potential upside of 32.9%. The day 50 moving average is 38.57 and the 200 day MA is 41.81. The company has a market capitalisation of $53,680m. Visit the company website at: https://www.bostonscientific.com [stock_market_widget type="chart" template="basic" color="green" assets="BSX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $71,359m based on the market concensus. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Lawyer says settlement will provide compensation for women who suffered pain and complications from pelvic mesh
Boston Scientific (NYSE: BSX ) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 20.73%. Currently, Boston Scientific has a market capitalization of $52.97 billion. Buying $100 In BSX: If … Full story available on Benzinga.com
Boston Scientific Corporation with ticker code (BSX) now have 25 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 55.5 and 43 with the average target price sitting at 49.03. Given that the stocks previous close was at 37.85 this would indicate that there is a potential upside of 29.5%. The 50 day MA is 39.09 and the 200 moving average now moves to 41.99. The market capitalisation for the company is $54,095m. Find out more information at: https://www.bostonscientific.com [stock_market_widget type="chart" template="basic" color="green" assets="BSX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $70,073m based on the market concensus. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Boston Scientific''s (NYSE: BSX ) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short , which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
MARLBOROUGH, Mass., June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2022 on Wednesday, July 27, 2022 at 8:00 a.m. EDT. The call will be…